Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherap...

Full description

Bibliographic Details
Main Author: Jeong Uk Lim
Format: Article
Language:English
Published: The Korean Academy of Tuberculosis and Respiratory Diseases 2023-01-01
Series:Tuberculosis and Respiratory Diseases
Subjects:
carcinoma, non-small-cell lung
protein kinase inhibitors
chemotherapy, adjuvant
recurrence
biomarkers
Online Access:http://e-trd.org/upload/pdf/trd-2022-0081.pdf

Similar Items

Similar Items